NEW YORK (GenomeWeb) – Biotech firm Sygnis said today that it is acquiring UK-based proteomics reagents company Expedeon.

The deal broadens Sygnis' genomics-focused product portfolio to include protein research and gives it access to Expedeon's sales forces in the US and Europe, the company said.

Sygnis will purchase Expedeon for €1.7 million ($1.9 million) in cash and an additional amount of stock, financing the transaction by issuing up to 20.5 million new shares, which will raise up to €20.5 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.